Dr. Clay Siegall Is Establishing A Connection Between DNA And Treating Cancer

Cancer is feared because of the disability and death it brings to millions of individuals every year. A rapid diagnosis and treatment are critical to a patients outcome. New windows have opened due to the advances in genetic testing in cancer research. Advanced techniques in treating and diagnosing cancer more effectively are becoming possible. One of the leaders in the industry is Clay Siegall who founded Seattle Genetics.

 

Humans have roughly 20,000 genes that form unique DNA codes. In the past it was not possible to extract this code. Advances in research have determined this code predisposes individuals to specific diseases such as cancer. There are other factors as well including environment and diet. These factors combine with genetic predispositions and scientists believe if a DNA code can be extracted quickly it can diagnose cancer and a targeted treatment can be created.

 

Cancer is a term describing hundreds of different diseases. The differences in the occurrence in individuals is based on genetics, hormones and an individuals biological makeup. This is why people with the same diagnosis respond differently when treated. Genetic sequencing takes each individuals DNA code into consideration. Prostate cancer is an excellent example because it previously involved months of bloodwork, biopsies and ultrasounds to achieve a diagnosis. New advancements allow a diagnosis within two weeks because it is targeted with their genetic profile.

 

In 1989 Seattle Genetics was co-founded by Dr. Clay Siegall. His leadership has allowed the company to develop diverse therapies for cancer including Adcetris which the U.S. Food and Drug Administration approved in 2011. He has been at the head of their fund raising and secured in excess of $675 million through both private and public financing.

 

Dr. Siegall served Bristol-Myers Squibb Pharmaceutical from 1991 until 1997 before he founded Seattle Genetics. From 1988 until 1991 he worked with the National Institute of Health and the National Cancer Institute. He is on the board for Alder BioPharmaceuticals which is a private biotechnology firm. He is an author, holds numerous patents, has a Ph.D. in Genetics and a B.S. in Zoology.

 

Comments are closed.